| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Aberrant spliceosome kinetics and structural variations drive the production of soluble PD-L1 mRNA in various cancer and immune cell types
|
Papamichos, S.I.
|
|
|
28 |
S11 |
p. xi24
|
artikel
|
| 2 |
Abundance of Treg cells in oral cancer patients and effects of their inhibition on growth of cancer cells
|
Aggarwal, S.
|
|
|
28 |
S11 |
p. xi26
|
artikel
|
| 3 |
A clinical insight into therapeutic sequence in advanced melanoma
|
Vera-Aguilera, J.
|
|
|
28 |
S11 |
p. xi23-xi24
|
artikel
|
| 4 |
A first-in-human phase I/II clinical trial assessing novel mRNA-lipoplex nanoparticles encoding shared tumor antigens for potent melanoma immunotherapy
|
Heesen, L.
|
|
|
28 |
S11 |
p. xi14-xi15
|
artikel
|
| 5 |
Antitumor effects of EGF-pathway immunization in NSCLC
|
Codony-Servat, J.
|
|
|
28 |
S11 |
p. xi17-xi18
|
artikel
|
| 6 |
A phase 1b/2 study of omaveloxolone in combination with checkpoint inhibitors in patients with unresectable or metastatic melanoma
|
Patel, S.P.
|
|
|
28 |
S11 |
p. xi30
|
artikel
|
| 7 |
A retrospective analysis of response to checkpoint inhibitors and its correlation to both PD-L1 score and tumor mutation burden in patients with solid tumor malignancies
|
Kazmi, S.M.
|
|
|
28 |
S11 |
p. xi10
|
artikel
|
| 8 |
A retrospective analysis to evaluate prevalence and correlation between PD-L1 score and tumor mutational burden (TMB) levels in patients with solid tumor malignancies
|
Kazmi, S.M.
|
|
|
28 |
S11 |
p. xi10-xi11
|
artikel
|
| 9 |
Arming oncolytic adenovirus with FAP-targeting bispecific T-cell engager to improve antitumor efficacy
|
de Sostoa Pomés, J.
|
|
|
28 |
S11 |
p. xi18
|
artikel
|
| 10 |
Association of p53-autoantibodies with TP53 somatic mutational profile detected by next generation sequencing in advanced high-grade ovarian cancer
|
Garziera, M.
|
|
|
28 |
S11 |
p. xi12
|
artikel
|
| 11 |
Association of PDL1 expression with TP53, KRAS mutation, and microsatellite instability in Indonesian patients with colorectal cancer
|
Putra, T.P.
|
|
|
28 |
S11 |
p. xi11
|
artikel
|
| 12 |
Biology of plasmacytoid dendritic cells in head and neck cancer
|
Koucký, V.
|
|
|
28 |
S11 |
p. xi25-xi26
|
artikel
|
| 13 |
Chemokine receptor 2 (CCR2) antagonism with a small molecule enhances the effectiveness of checkpoint inhibition by altering the tumor microenvironment in mouse colorectal tumours: Reducing tumor size and increasing long term survival
|
Campbell, J.
|
|
|
28 |
S11 |
p. xi20
|
artikel
|
| 14 |
Combination of brain radiotherapy (RT) and immunotherapy (IT) in a single Institution cohort of patients (pts) with metastatic melanoma (MM)
|
Galli, G.
|
|
|
28 |
S11 |
p. xi8
|
artikel
|
| 15 |
Combination therapy with nivolumab and PD-L1/IDO peptide vaccine to patients with metastatic melanoma. A clinical trial in progress
|
Kjeldsen, J.W.
|
|
|
28 |
S11 |
p. xi27-xi28
|
artikel
|
| 16 |
Combined immunotherapy encompassing intratumoral polyICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients
|
Rodríguez-Ruiz, M.E.
|
|
|
28 |
S11 |
p. xi14
|
artikel
|
| 17 |
Deciphering the intra-tumoural T cell receptor repertoire in patients with NSCLC within the lung TRACERx study
|
Joshi, K.
|
|
|
28 |
S11 |
p. xi2
|
artikel
|
| 18 |
Delivering complete responses against solid tumors by checkpoint blockade enabled with tumor necrosis factor alpha and interleukin-2 armed adenoviruses
|
Cervera-Carrascon, V.
|
|
|
28 |
S11 |
p. xi15
|
artikel
|
| 19 |
Development of circulating anti-drug antibodies associate with shortened survival in patients with metastatic malignant melanoma treated with ipilimumab
|
Kverneland, A.
|
|
|
28 |
S11 |
p. xi21
|
artikel
|
| 20 |
Differential expression of PD-L1, MALAT1 and XIST in tumors and lymph nodes of TNBC and IDC patients and their regulation by miR-182
|
Samir, A.
|
|
|
28 |
S11 |
p. xi12
|
artikel
|
| 21 |
Divergent PD-1 expression in tissue and circulating CD8 lymphocytes defines an immune profile predictive of the response to nivolumab in advanced NSCLC
|
Mazzaschi, G.
|
|
|
28 |
S11 |
p. xi9
|
artikel
|
| 22 |
Down-regulated miR-486-5p acts as a tumor suppressor in breast cancer patients by targeting the metastatic mediator ICAM-1
|
Abdallah, R.
|
|
|
28 |
S11 |
p. xi22
|
artikel
|
| 23 |
Drug Index
|
|
|
|
28 |
S11 |
p. xi32
|
artikel
|
| 24 |
Durable remissions associated with anti-CTLA-4 and anti-PD1 checkpoint inhibitors in a single center
|
Smit, T.
|
|
|
28 |
S11 |
p. xi6
|
artikel
|
| 25 |
Editorial Board
|
|
|
|
28 |
S11 |
p. ii-iii
|
artikel
|
| 26 |
Effect of ciclopirox olamine in immunotherapy effect by stimulating immunogenic cell death in pancreatic cancer
|
Mihailidou, C.
|
|
|
28 |
S11 |
p. xi21
|
artikel
|
| 27 |
Efficacy of a multipeptide bcr-abl p210 protein derived vaccine in chronic myeloid leukemia with 5-year follow up
|
Osfouri, E.
|
|
|
28 |
S11 |
p. xi15
|
artikel
|
| 28 |
Efficacy of PEGylated human IL-10 (AM0010) in combination with anti-PD-1 blockade in patients (pts) with metastatic renal cell carcinoma (mRCC): A phase 1b trial
|
Naing, A.
|
|
|
28 |
S11 |
p. xi1
|
artikel
|
| 29 |
Engineering T-cells for adoptive cell therapy to overcome TGF-β-mediated immunosuppression in the tumour microenvironment
|
Catchpole, I.
|
|
|
28 |
S11 |
p. xi27
|
artikel
|
| 30 |
Evaluating renal cell carcinoma treatment options using real world data: Findings from an oncology survey across seven countries
|
Mpima, S.
|
|
|
28 |
S11 |
p. xi6
|
artikel
|
| 31 |
Evaluation the effect of Brucella abortus RB51 lipopolysaccharide as an adjuvant on the efficiency of HPV-16 L1 and HPV-16 E7 DNA vaccines in C57BL/6 mice
|
Soleimanjahi, H.
|
|
|
28 |
S11 |
p. xi18
|
artikel
|
| 32 |
Expansion of tumor specific tumor-infiltrating lymphocytes (TIL) from sarcoma and the potential benefit of anti-CD137 stimulation: A prerequisite for adoptive cell transfer (ACT) immunotherapy
|
Nielsen, M.
|
|
|
28 |
S11 |
p. xi4
|
artikel
|
| 33 |
Experience of immune-related adverse events associated with anti-CTLA-4 and anti-PD1 checkpoint inhibitors in a single center
|
Rapoport, B.L.
|
|
|
28 |
S11 |
p. xi7
|
artikel
|
| 34 |
Expression pattern of immune checkpoints programmed death (PD-1) and programmed death-ligand (PD-L1) in retinoblastoma and its prognostic significance
|
Singh, L.
|
|
|
28 |
S11 |
p. xi11
|
artikel
|
| 35 |
Extended survival analysis of ipilimumab for the treatment of advanced malignant melanoma in pretreated patients: Five-year long-term follow-up of the South African expanded access program
|
Rapoport, B.L.
|
|
|
28 |
S11 |
p. xi6
|
artikel
|
| 36 |
Extracellular vesicle-internalizing receptors (EVIRs) for dendritic cell-based tumor vaccines
|
Squadrito, M.L.
|
|
|
28 |
S11 |
p. xi15
|
artikel
|
| 37 |
Flowcytometric expression of LAIR-1 inhibitory immune-receptor in pediatric acute lymphoblastic leukemia cases does not correlate with standard risk factors and minimal residual disease
|
Bhatia, P.
|
|
|
28 |
S11 |
p. xi26
|
artikel
|
| 38 |
Gastric cancer stem-like cells, the balance operator of Th17 and Treg
|
Rezalotfi, A.
|
|
|
28 |
S11 |
p. xi26-xi27
|
artikel
|
| 39 |
Generation and characterization of cord blood derived T cells redirected with a TCR targeting E7/HLA-DR4 complex
|
Marton, C.
|
|
|
28 |
S11 |
p. xi19-xi20
|
artikel
|
| 40 |
Health-related quality of life (HRQoL) in patients (Pts) with Merkel cell carcinoma (MCC) receiving avelumab
|
Bharmal, M.
|
|
|
28 |
S11 |
p. xi23
|
artikel
|
| 41 |
Helicobacter pylori CagA expression is closely associated with tumor PD-L1 expression and the better prognosis of gastric cancer patients
|
Kuo, S-H
|
|
|
28 |
S11 |
p. xi10
|
artikel
|
| 42 |
Homology between cancer and viral epitopes as criteria to design improved cancer vaccines
|
Capasso, C.
|
|
|
28 |
S11 |
p. xi18
|
artikel
|
| 43 |
Identification of subsets of tumor infiltrating lymphocytes in primary brain tumors using multi-color panel flow cytometry
|
Ben-Horin, I.
|
|
|
28 |
S11 |
p. xi25
|
artikel
|
| 44 |
IMA950 multipeptide vaccine adjuvanted with poly-ICLC in combination with standard therapy in newly diagnosed HLA-A2 glioblastoma patients
|
Dutoit, V.
|
|
|
28 |
S11 |
p. xi3-xi4
|
artikel
|
| 45 |
Immune checkpoint vaccines and radiation combination strategy
|
Lan, K-H
|
|
|
28 |
S11 |
p. xi16
|
artikel
|
| 46 |
Immune-mediated cystatin A expression in patients with pancreatic ductal adenocarcinoma
|
Komura, T.
|
|
|
28 |
S11 |
p. xi21-xi22
|
artikel
|
| 47 |
Immunomonitoring of patients treated with personalized dendritic cell-based vaccine
|
Fedorova, L.
|
|
|
28 |
S11 |
p. xi17
|
artikel
|
| 48 |
Immunotherapy enhanced by geroprotection: Hormone-resistant prostate cancer
|
Lasalvia-Prisco, E.M.
|
|
|
28 |
S11 |
p. xi22-xi23
|
artikel
|
| 49 |
Impairment of membrane TNFα expression reduces cytotoxic activity of dendritic cells against autologous tumor cells in high-grade glioma patients
|
Tyrinova, T.
|
|
|
28 |
S11 |
p. xi25
|
artikel
|
| 50 |
Influenza vaccine indication during anticancer therapy with immune-checkpoint inhibitors: A transversal challenge for patient’s counselling – preliminary analysis of the INVIDIa study
|
Bersanelli, M.
|
|
|
28 |
S11 |
p. xi17
|
artikel
|
| 51 |
INO-5150 (PSA and PSMA) +/- INO-9012 (IL-12) immunotherapy in biochemically relapsed prostate cancer
|
Csiki, I.
|
|
|
28 |
S11 |
p. xi5
|
artikel
|
| 52 |
In patients with advanced non-small cell lung cancer (NSCLC) LAG-3 is expressed on activated TILs and predicts resistance to PD-1 axis blockers
|
Datar, I.
|
|
|
28 |
S11 |
p. xi5
|
artikel
|
| 53 |
Ipilimumab for advanced melanoma in the real world: The Northern Ireland experience
|
Gallagher, P.F.
|
|
|
28 |
S11 |
p. xi6-xi7
|
artikel
|
| 54 |
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
|
Miller, M.
|
|
|
28 |
S11 |
p. xi1-xi2
|
artikel
|
| 55 |
KEYNOTE-629: Phase 2 trial of pembrolizumab in patients (pts) with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC)
|
Licitra, L.
|
|
|
28 |
S11 |
p. xi28-xi29
|
artikel
|
| 56 |
Markers of inflammation as prognostic factors for survival in peripheral T-cell lymphoma in Peru
|
Castro, D.
|
|
|
28 |
S11 |
p. xi13
|
artikel
|
| 57 |
Mechanistic divergence of immune checkpoint inhibition by an ex vivo platform derived from patient tumors where tumor and immune microenvironment is preserved
|
Biswas, M.
|
|
|
28 |
S11 |
p. xi25
|
artikel
|
| 58 |
miR-4317, a novel tumor suppressor miRNA, alleviates immune-suppressive microenvironment induced by breast cancer
|
Youness, R.A.
|
|
|
28 |
S11 |
p. xi23
|
artikel
|
| 59 |
Modulation of the tumor microenvironment by the TLR9 agonist EnanDIM and combination with checkpoint inhibition for cancer immunotherapy
|
Kapp, K.
|
|
|
28 |
S11 |
p. xi16
|
artikel
|
| 60 |
Mutanome engineered RNA immuno-therapy (MERIT) for patients with triple negative breast cancer
|
Frenzel, K.
|
|
|
28 |
S11 |
p. xi29
|
artikel
|
| 61 |
NK-cell based delivery of anticancer therapeutics
|
Koval, O.
|
|
|
28 |
S11 |
p. xi20
|
artikel
|
| 62 |
Novel and promising therapeutic approaches for glioblastoma: Blocking CD47-SIRPα axis alone or combined with autophagy depletion
|
Zhang, X.
|
|
|
28 |
S11 |
p. xi4
|
artikel
|
| 63 |
Novel dual arginase 1/2 inhibitor OATD-02 (OAT-1746) improves the efficacy of immune checkpoint inhibitors
|
Grzybowski, M.M.
|
|
|
28 |
S11 |
p. xi20-xi21
|
artikel
|
| 64 |
Oncolytic adenovirus expressing tumor neoepitopes as a vaccine
|
Sal, M Farrera
|
|
|
28 |
S11 |
p. xi15-xi16
|
artikel
|
| 65 |
Oncolytic virotherapy using the chimeric rhabdovirus VSV-GP: Tumor-selective induction of cell death and immune-activation
|
Wollmann, G.
|
|
|
28 |
S11 |
p. xi17
|
artikel
|
| 66 |
Optimizing the tolerability of intravenous oncolytic viral immunotherapy administration: A sub-analysis of tolerability and cytokine data from the EVOLVE study of enadenotucirev (EnAd), an oncolytic adenovirus
|
McElwaine-Johnn, H.
|
|
|
28 |
S11 |
p. xi14
|
artikel
|
| 67 |
Patient characteristics after completion of recruitment from the phase 3 IMPALA study with lefitolimod in metastatic colorectal carcinoma
|
Cunningham, D.
|
|
|
28 |
S11 |
p. xi27
|
artikel
|
| 68 |
PEGylated human IL-10 (AM0010) in combination with an anti-PD-1 in advanced NSCLC
|
Wong, D.
|
|
|
28 |
S11 |
p. xi3
|
artikel
|
| 69 |
Pembrolizumab (pembro) for relapsed malignant pleural mesothelioma (MPM): Outcomes in real-life setting in Australia (AUS) and Switzerland (CH)
|
Mauti, L.
|
|
|
28 |
S11 |
p. xi8
|
artikel
|
| 70 |
Peptide-MHC-directed expansion of multifunctional antigen-responsive T cells
|
Rasmussen, V.M.
|
|
|
28 |
S11 |
p. xi20
|
artikel
|
| 71 |
Peptide vaccination against PD-L1 in multiple myeloma: A phase I trial
|
Jørgensen, N.G.
|
|
|
28 |
S11 |
p. xi28
|
artikel
|
| 72 |
Phase 3 KEYNOTE-412 trial: Pembrolizumab plus chemoradiation (CRT) vs CRT alone for locally advanced head and neck squamous cell carcinoma (LA-HNSCC)
|
Machiels, J-P
|
|
|
28 |
S11 |
p. xi28
|
artikel
|
| 73 |
Phase 1 study of E7046, a PGE2 receptor EP-4 inhibitor that targets immunosuppressive myeloid cells in the tumor microenvironment (TME)
|
Hong, D.
|
|
|
28 |
S11 |
p. xi1
|
artikel
|
| 74 |
Plasma levels of interleukin-33 (IL-33) and soluble suppression of tumorigenicity 2 (sST2) as a potential predictive biomarker in patients (pts) with advanced pancreatic ductal adenocarcinoma (PDAC) undergoing systemic chemotherapy (sCTX)
|
Kieler, M.
|
|
|
28 |
S11 |
p. xi11-xi12
|
artikel
|
| 75 |
PRAME, cell migration and invasion of triple negative breast cancer cells
|
Al-Sulaiti, B.
|
|
|
28 |
S11 |
p. xi26
|
artikel
|
| 76 |
Predictive effect of cytokines in non-small cell lung cancer
|
Huber, R.M.
|
|
|
28 |
S11 |
p. xi11
|
artikel
|
| 77 |
Pre-existing antitumor CD4 Th1 immunity in blood and PD-1/TIM-3+ CD4 T cells predict distinct outcome in lung cancer
|
Dosset, M.
|
|
|
28 |
S11 |
p. xi8-xi9
|
artikel
|
| 78 |
Presence of naturally occurring anti-telomerase CD4 Th1 immunity in glioblastoma
|
Meynard, G.
|
|
|
28 |
S11 |
p. xi24
|
artikel
|
| 79 |
Pretherapeutic inflammation status and cytokine profile may predict response to immunotherapy in NSCLC patients
|
Kauffmann-Guerrero, D.
|
|
|
28 |
S11 |
p. xi12
|
artikel
|
| 80 |
Primary PFS and safety analyses of a randomized phase III study of carboplatin + paclitaxel +/− bevacizumab, with or without atezolizumab in 1L non-squamous metastatic nsclc (IMPOWER150)
|
Reck, M.
|
|
|
28 |
S11 |
p. xi31
|
artikel
|
| 81 |
Priming and expansion of neo-antigen specific-T cells thanks to an off-the-shelf cell-based drug product
|
Plumas, J.
|
|
|
28 |
S11 |
p. xi18-xi19
|
artikel
|
| 82 |
Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich
|
Sanoyan, D Akhoundova
|
|
|
28 |
S11 |
p. xi7
|
artikel
|
| 83 |
Real world analysis for immune related side effects in 3000 patients
|
Mitrofan, L.
|
|
|
28 |
S11 |
p. xi7-xi8
|
artikel
|
| 84 |
Replacing lymphodepleting preconditioning with an oncolytic adenovirus coding for tumor necrosis factor alpha and interleukin-2 in adoptive cell therapy
|
Santos, J.M.
|
|
|
28 |
S11 |
p. xi19
|
artikel
|
| 85 |
Selective internal radiation therapy (SIRT) promotes the recruitment of tumor-infiltrating lymphocytes and enhances cytotoxic activity in hepatocellular carcinoma
|
Craciun, L.
|
|
|
28 |
S11 |
p. xi3
|
artikel
|
| 86 |
Serological assessment of extracellular matrix (ECM) remodeling in relation to clinical response in metastatic melanoma patients treated with ipilimumab
|
Jensen, C.
|
|
|
28 |
S11 |
p. xi10
|
artikel
|
| 87 |
STAT3 inhibition reduces self-renewal in gastric cancer and promotes immune activation
|
Ebrahimi, M.
|
|
|
28 |
S11 |
p. xi22
|
artikel
|
| 88 |
Table of Contents
|
|
|
|
28 |
S11 |
p. iv
|
artikel
|
| 89 |
Targeting lymphoma with CD37CAR: A pre-clinical study
|
Walchli, S.
|
|
|
28 |
S11 |
p. xi5
|
artikel
|
| 90 |
T cell recognition of breast cancer antigens
|
Ramskov, S.
|
|
|
28 |
S11 |
p. xi19
|
artikel
|
| 91 |
T cell responses in patients with melanoma resistant to multiple immunotherapies
|
Andersen, R.
|
|
|
28 |
S11 |
p. xi4
|
artikel
|
| 92 |
T-cell therapy: Enabling oncolytic adenoviruses for the treatment of melanoma
|
Santos, J.M.
|
|
|
28 |
S11 |
p. xi16
|
artikel
|
| 93 |
T-cell therapy in combination with vemurafenib in BRAF mutated metastatic melanoma patients
|
Borch, T.H.
|
|
|
28 |
S11 |
p. xi29
|
artikel
|
| 94 |
TGF-β signalling attenuates tumour response to PD-L1 checkpoint blockade by contributing to retention of T cells in the peritumoural stroma
|
Mariathasan, S.
|
|
|
28 |
S11 |
p. xi30
|
artikel
|
| 95 |
The association of the level of serum of interleukin-10 and its polymorphism gene with the risk and the prognosis for colorectal cancer in Tunisia
|
Braham, J.A.
|
|
|
28 |
S11 |
p. xi13
|
artikel
|
| 96 |
The immune modulation role of low dosage of cyclosporin-A (ldCSA) in the antitumor response of CD8+ T lymphocytes (CD8+Tcells) and the implication of neuropilin-1 (Nrp1)
|
Flores, C.
|
|
|
28 |
S11 |
p. xi21
|
artikel
|
| 97 |
Therapy-induced priming of natural killer cells predicts patient-specific tumor rejection in multiple breast cancer indications
|
Smalley, M.
|
|
|
28 |
S11 |
p. xi9
|
artikel
|
| 98 |
The role of IL10, IL6 and TNFα as potential prognostic markers in breast cancer in Tunisia
|
Braham, J.A.
|
|
|
28 |
S11 |
p. xi13
|
artikel
|
| 99 |
Translational Research Index
|
|
|
|
28 |
S11 |
p. xi33
|
artikel
|
| 100 |
Tumor-infiltrating lymphocytes, tumor-associated macrophages and HLA class 1 expression in breast cancer patients treated with neoadjuvant chemotherapy with or without zoledronic acid: A sub study of the NEOZOTAC trial
|
de Groot, A.F.
|
|
|
28 |
S11 |
p. xi9
|
artikel
|
| 101 |
XIST and TSIX: Novel cancer-immune biomarkers showing differential expression in tumor, PBMCs, serum, nipple discharge and lymph nodes of PD-L1 overexpressing BC patients
|
Atef, E.
|
|
|
28 |
S11 |
p. xi13
|
artikel
|
Tijdschrift beschrijving